BrainSee

Diagnostics and imaging · by Darmiyan

First FDA-approved medical software designed to help physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI) by combining a patient's brain MRI with cognitive test scores to generate a likelihood score for progression to Alzheimer's dementia.

What it does

First FDA-approved medical software designed to help physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI) by combining a patient's brain MRI with cognitive test scores to generate a likelihood score for progression to Alzheimer's dementia.

  • Early detection of Alzheimer's disease
  • Monitoring patient-specific response to interventions
  • Advancing drug development for Alzheimer's disease
Category
Diagnostics and imaging
Built for
Healthcare and life sciences
Users
physicians, patients, pharmaceutical companies
Public API
Not offered

Not yet disclosed: deployment options, platforms, languages and support channels.

Pricing

Pricing isn't published

Darmiyan doesn't list prices publicly. Ask them for a quote.

Security and compliance

As reported by Darmiyan. Ask for audit reports before you buy.

  • FDA De Novo ApprovalCompliant
  • FDA Breakthrough DesignationCompliant

Reviews

No reviews yet

Reviews come from people who use BrainSee at work. Share how your team uses it to help other buyers decide.

Alternatives

Is this your product?

Claim it to keep details accurate and submit evidence for the next ranking review.

Claim BrainSee